Alnylam Pharmaceuticals Inc (ALNY)vsBeiGene, Ltd. (ONC)
ALNY
Alnylam Pharmaceuticals Inc
$312.17
+0.34%
HEALTHCARE · Cap: $42.29B
ONC
BeiGene, Ltd.
$282.72
+0.15%
HEALTHCARE · Cap: $32.42B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 44% more annual revenue ($5.34B vs $3.71B). ALNY leads profitability with a 8.4% profit margin vs 5.4%. ONC trades at a lower P/E of 114.8x. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1934.6%
Fair Value
$15.84
Current Price
$312.17
$296.33 premium
Margin of Safety
-1999.6%
Fair Value
$16.73
Current Price
$282.72
$265.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 52.4x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 136.9x leaves little room for execution misses.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 114.8x leaves little room for execution misses.
Key Dynamics to Monitor
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 42/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?